Eagle Capital Management (New York)’s Thermo Fisher Scientific TMO Stock Holding History

Eagle Capital Management (New York)’s Portfolio TMO Stock Details TMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-683	Closed	-$340K	–	59
2025 Q1	$340K	Hold	683	–	–	﹤0.01%	56
2024 Q4	$355K	Hold	683	–	–	﹤0.01%	47
2024 Q3	$422K	Sell	683 -180	-21%	-$107K	﹤0.01%	45
2024 Q2	$477K	Sell	863 -244	-22%	-$140K	﹤0.01%	45
2024 Q1	$643K	Sell	1,107 -95	-8%	-$53.3K	﹤0.01%	45
2023 Q4	$638K	Hold	1,202	–	–	﹤0.01%	44
2023 Q3	$608K	Hold	1,202	–	–	﹤0.01%	41
2023 Q2	$627K	Hold	1,202	–	–	﹤0.01%	43
2023 Q1	$693K	Hold	1,202	–	–	﹤0.01%	41
2022 Q4	$662K	Sell	1,202 -27,489	-96%	-$14.6M	﹤0.01%	44
2022 Q3	$14.6M	Hold	28,691	–	–	0.07%	33
2022 Q2	$15.6M	Hold	28,691	–	–	0.07%	33
2022 Q1	$16.9M	Hold	28,691	–	–	0.06%	31
2021 Q4	$19.1M	Hold	28,691	–	–	0.06%	31
2021 Q3	$16.4M	Hold	28,691	–	–	0.05%	30
2021 Q2	$14.5M	Sell	28,691 -94	-0.3%	-$44.4K	0.04%	30
2021 Q1	$13.1M	Hold	28,785	–	–	0.04%	31
2020 Q4	$13.4M	Hold	28,785	–	–	0.04%	32
2020 Q3	$12.7M	Hold	28,785	–	–	0.05%	35
2020 Q2	$10.4M	Sell	28,785 -294	-1%	-$98.5K	0.04%	35
2020 Q1	$8.25M	Sell	29,079 -136	-0.5%	-$42.9K	0.03%	38
2019 Q4	$9.49M	Sell	29,215 -72	-0.2%	-$21.8K	0.03%	38
2019 Q3	$8.53M	Hold	29,287	–	–	0.03%	37
2019 Q2	$8.6M	Buy	29,287 +117	+0.4%	+$32.2K	0.03%	39
2019 Q1	$7.98M	Sell	29,170 -4,062	-12%	-$1.01M	0.03%	39
2018 Q4	$7.44M	Sell	33,232 -3,246,712	-99%	-$762M	0.03%	40
2018 Q3	$801M	Sell	3,279,944 -84,184	-3%	-$19.4M	2.75%	14
2018 Q2	$697M	Sell	3,364,128 -74,201	-2%	-$15.8M	2.53%	16
2018 Q1	$710M	Sell	3,438,329 -97,159	-3%	-$20.4M	2.63%	17
2017 Q4	$671M	Sell	3,535,488 -82,619	-2%	-$15.8M	2.49%	19
2017 Q3	$685M	Sell	3,618,107 -47,734	-1%	-$8.64M	2.64%	18
2017 Q2	$640M	Sell	3,665,841 -107,953	-3%	-$18.1M	2.5%	19
2017 Q1	$580M	Sell	3,773,794 -89,818	-2%	-$13.7M	2.37%	19
2016 Q4	$545M	Sell	3,863,612 -206,470	-5%	-$30.4M	2.31%	20
2016 Q3	$647M	Sell	4,070,082 -249,071	-6%	-$38.4M	2.79%	16
2016 Q2	$638M	Sell	4,319,153 -139,509	-3%	-$20.6M	2.74%	16
2016 Q1	$631M	Sell	4,458,662 -3,876	-0.1%	-$519K	2.64%	16
2015 Q4	$633M	Buy	4,462,538 +61,391	+1%	+$8.19M	2.59%	18
2015 Q3	$538M	Sell	4,401,147 -30,500	-0.7%	-$3.97M	2.36%	18
2015 Q2	$575M	Sell	4,431,647 -542,680	-11%	-$70.7M	2.26%	21
2015 Q1	$668M	Sell	4,974,327 -79,844	-2%	-$10.3M	2.48%	19
2014 Q4	$633M	Sell	5,054,171 -173,926	-3%	-$21.1M	2.39%	18
2014 Q3	$636M	Sell	5,228,097 -19,985	-0.4%	-$2.43M	2.46%	19
2014 Q2	$619M	Sell	5,248,082 -277,416	-5%	-$32.6M	2.45%	21
2014 Q1	$664M	Sell	5,525,498 -193,588	-3%	-$23M	2.7%	18
2013 Q4	$637M	Sell	5,719,086 -26,910	-0.5%	-$2.68M	2.72%	19
2013 Q3	$529M	Buy	5,745,996 +2,113	+0%	+$191K	2.57%	19
2013 Q2	$486M	Buy	+5,743,883	New	+$478M	2.6%	19

Other funds holding TMO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Eagle Capital Management (New York)'s TMO Position: Q2 2025 in Review

Eagle Capital Management (New York) sold out of Thermo Fisher Scientific (TMO) in Q2 2025, closing a stake of 683 shares — an estimated $340K sold.

Eagle Capital Management (New York) first reported a position in TMO in Q2 2013 and held it in 48 quarters. The position peaked at $801M in Q3 2018. 2,458 funds tracked by Wall St. Rank hold TMO as of Q2 2025.

Eagle Capital Management (New York) reported no remaining Thermo Fisher Scientific position as of Q2 2025 after selling out during the quarter.
Eagle Capital Management (New York) sold 683 Thermo Fisher Scientific shares in Q2 2025, an estimated $340K.
Eagle Capital Management (New York) first reported a position in Thermo Fisher Scientific in Q2 2013 and held it in 48 quarters.
Eagle Capital Management (New York)'s Thermo Fisher Scientific position peaked at $801M in Q3 2018.
2,458 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2025.

Based on Eagle Capital Management (New York)'s 13F filing for Q2 2025, filed 14 Aug 2025.